Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia
DUBLIN (BUSINESS WIRE) Mainstay Medical Holdings plc (“
Mainstay” or the “
Company”) today announced the commercial launch in Australia of ReActiv8®, its implantable neurostimulation system to treat chronic low back pain.
“Launching ReActiv8, our Restorative Neurostimulation therapy, commercially in Australia is a significant milestone for our global commercial expansion. Several top Australian physicians have been part of our clinical studies since inception and are among the most experienced globally in selecting and treating patients with ReActiv8. We are excited to make ReActiv8 commercially available to Australian physicians and their patients suffering from mechanical chronic low back pain,”
Press release content from Business Wire. The AP news staff was not involved in its creation.
Mainstay Medical Announces Key Strategic Hires to Drive Global Commercial Expansion
January 25, 2021 GMT
DUBLIN (BUSINESS WIRE) Jan 25, 2021
Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced recent senior leadership additions as part of its global commercial strategy. These include: Elias Tu as Vice President of U.S. Sales; Derek Matteo as Vice President of Marketing; James Knibbs as Vice President of UK, Ireland, and Australia; Boris Deutschmann as Country Manager for Germany; Chip Moebus as Vice President of Reimbursement and Market Access; Richard Herman as Vice President of Operations; and Celia Reyes as Vice President of Human Resources.